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Abstract
Background: Paraneoplastic retinopathy (PR), including cancer-associated retinopathy (CAR) and melanoma-associated
retinopathy (MAR), is a progressive retinal disease caused by antibodies generated against neoplasms not associated with
the eye. While several autoantibodies against retinal antigens have been identified, there has been no known autoantibody
reacting specifically against bipolar cell antigens in the sera of patients with PR. We previously reported that the transient
receptor potential cation channel, subfamily M, member 1 (TRPM1) is specifically expressed in retinal ON bipolar cells and
functions as a component of ON bipolar cell transduction channels. In addition, this and other groups have reported that
human TRPM1 mutations are associated with the complete form of congenital stationary night blindness. The purpose of
the current study is to investigate whether there are autoantibodies against TRPM1 in the sera of PR patients exhibiting ON
bipolar cell dysfunction.
Methodology/Principal Findings: We performed Western blot analysis to identify an autoantibody against TRPM1 in the
serum of a patient with lung CAR. The electroretinograms of this patient showed a severely reduced ON response with
normal OFF response, indicating that the defect is in the signal transmission between photoreceptors and ON bipolar cells.
We also investigated the sera of 26 patients with MAR for autoantibodies against TRPM1 because MAR patients are known
to exhibit retinal ON bipolar cell dysfunction. Two of the patients were found to have autoantibodies against TRPM1 in their
sera.
Conclusion/Significance: Our study reveals TRPM1 to be one of the autoantigens targeted by autoantibodies in at least
some patients with CAR or MAR associated with retinal ON bipolar cell dysfunction.
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Introduction
Paraneoplastic retinopathy (PR) is a progressive retinal disorder
caused by an autoimmune mechanism and is associated with the
presence of anti-retinal antibodies in the serum generated against
neoplasms not associated with the eye [1–4]. The retinopathy can
develop either before or after the diagnosis of a neoplasm. Patients
with PR can have night blindness, photopsia, ring scotoma,
attenuated retinal arteriole, and abnormal electroretinograms
(ERGs). The diagnosis of PR is usually made by the identification
of neoplasms and anti-retinal autoantibodies in the sera.
PR includes two subgroups: cancer-associated retinopathy (CAR)
[5,6] and melanoma-associated retinopathy(MAR) [7–10]. Although
CAR and MAR share similar clinical symptoms, the ERG findings
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19911are very different. Both a- and b-waves are severely attenuated in
CAR, indicating extensive photoreceptor dysfunction, whereas only
the b-wave is severely reduced while the a-wave is normal in MAR,
suggesting bipolar cell dysfunction [8,9]. However, it was recently
reported that cancers other than melanoma can cause bipolar cell
dysfunction [11,12]. Several autoantibodies against retinal antigens
have been identified, but a specific antigen associated with bipolar
cells has not been identified in patients with CAR and MAR [1–10].
In the current study, we identified autoantibodies against the
transient receptor potential cation channel, subfamily M, member 1
(TRPM1) [13–15] in the serum of one patient with lung cancer. The
ERG findings in this patient indicated a selective ON-bipolar cell
dysfunction. We also investigated the sera of 26 MAR patients and
found that two contained autoantibodies against TRPM1. Our
results suggest that TRPM1 is one of the retinal autoantigens in at
least some patients with CAR or MAR and may cause retinal ON
bipolar cell dysfunction.
Results
Case report of CAR associated with ON bipolar cell
dysfunction
A 69-year-old man visited the Nagoya University Hospital with
complaints of blurred vision, photopsia and night blindness in both
eyes of three months duration. At this point he was not diagnosed
as suffering from any eye disease or systemic disease, including a
malignant tumor, and his family history revealed no other
members suffering from any eye diseases. On initial examination,
his best-corrected visual acuity was 0.9 in the right eye and 0.6 in
the left eye. Humphrey static perimetry revealed a severe decrease
in sensitivity within the central 30 degrees of the visual field in both
eyes (Fig. 1A). Dark-adaptometry of this patient showed a loss of
the rod branch. The cone threshold was within normal range.
Ophthalmoscopy showed a nearly normal fundus appearance
except for slight hypopigmentation at the macula of the left eye,
which may be due to age-related changes in the retinal pigment
epithelium (Fig. 1B), but fluorescein angiography demonstrated
periphlebitis of the retinal vessels (arrows, Fig. 1C). Spectral-
domain optical coherence tomography (SD-OCT) showed that the
morphology of the retina was normal in both eyes (Fig. 1D).
Electrophysiological examinations
Recordings of the full-field ERGs from this patient showed that the
rod responses were undetectable (Fig. 2). The rod- and cone-mixed
maximal response was a negative-type with an a-wave of normal
amplitude and a b-wave that was smaller than the a-wave. The a-
wave of the cone response had a wide trough, and the b-wave was
reduced by 40%. The amplitude of the 30-Hz flicker ERG was
reduced by 50%. The photopic long-flash ERG showed severely
reduced ON response and normal OFF response. These ERG
findings indicated that there was a defect in the signal transmission
from photoreceptors to ON bipolar cells both in both rod and cone
pathways.
Based on these ophthalmological and electrophysiological tests,
we suspected that this patient might have PR and referred him to an
internist. The general physical examination including positron
emission tomography and computed tomography revealed two
abnormal massesintheright lung.Biopsy ofthese massesconfirmed
that the masses were small cell carcinomas of the lung.
Detection of autoantibodies against TRPM1 in the serum
of the CAR patient
Based on our ERG examination results, we hypothesized that
the serum of this CAR patient may contain autoantibodies against
TRPM1. To test this hypothesis, we examined whether or not this
CAR patient’s serum could recognize human TRPM1 protein by
Western blot analysis. We transfected an expression plasmid
containing human TRPM1 cDNA with the C-terminal 3xFlag-tag
(TRPM1-3xFlag) into HEK293T cells, and carried out a Western
blot analysis using whole cell extracts harvested after 48 hrs cell
growth. We first confirmed that TRPM1-3xFlag was expressed by
cell using Western blot analysis and an anti-Flag antibody. We
detected the ,200 kDa TRPM1-3xFlag band in the cell lysates
(Fig. 3A).
Next, we performed Western blot analysis on the same lysates
using the serum from our CAR patient and a healthy control
person. We detected immunostaining of the same size protein,
which was confirmed with the anti-Flag antibody, and with CAR
serum. The control serum did not present a significant band
(Fig. 3B, C). This result showed the presence of autoantibodies
against TRPM1 in this CAR patient’s serum.
Figure 1. Ophthalmological findings from a patient with
paraneoplastic retinopathy (PR) associated with lung cancer.
(A) Threshold of static visual field (Humphrey, 30-2 program) plotted on
a gray scale showing severely decreased sensitivities within the central
30 degrees of the visual field. (B) Fundus photographs of the patient
showing a nearly normal fundus. (C) Fluorescein angiograms showing
periphlebitis of the retinal vessels (arrows). (D) Spectral-domain optical
coherence tomographic (SD-OCT) image of a 9 mm horizontal scan of
the retina of our patient. The retinal structure in each retinal layer is
normal.
doi:10.1371/journal.pone.0019911.g001
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retinal bipolar cells, we carried out an immunohistochemical
analysis on monkey and mouse retinas. We first performed
immunohistochemistry on the retina of a 3-year-old rhesus monkey
(Macaca mulata) and on the retina of a one-month-old C57/B6
mouse using the serum of the CAR patient, however, we did not
obtain a significant staining signal above background (data not
shown). We then concentrated the serum by IgG purification
followed by filter spin column centrifugation and performed
immunohistochemistry on the monkey retina using the concentrat-
ed serum (Fig. 3D–G). We observed a significant immunolabeling
on the INL in the monkey retina (Fig. 3D, F) whereas the normal
serum did not give a significant labeling (Fig. 3E, G). The antibodies
immuolabeled both the bipolar side and amacrine side of the INL.
Since most of the cells residing on the outer side of the INL are ON
bipolar cells, at leastsomeofthe stainedcellsare ONbipolar cells. It
should be noted some of the staining signals show a spotted pattern
in the outer plexiform layer (Fig. 3F) as is observed in TRPM1 or
mGluR6 immunostaining on the mouse retina [13], suggesting that
the CAR patient serum recognizes the bipolar dendritic tips where
some of the TRPM1 protein localizes.
Western blot analysis of the sera from MAR patients
Since the functional defect in the retina of MAR patients is
known to be due to abnormal signal transmission between
photoreceptors and ON bipolar cells [8,9], we then investigated
whether or not autoantibodies to TRPM1 were also present in the
sera of MAR patients. We obtained the sera of 26 MAR patients
from two hospitals in Japan (Chiba University Hospital and Iwate
Medical University Hospital) and Ocular Immunology Laboratory
in the USA (Casey Eye Institute). We found that the sera from
patients #8 and #23 exhibited a significant immunoreactive band
against TRPM1-transfected cell lysates by Western blot analysis
(Fig. 4A and B). The control serum showed no significant immune
response against the TRPM1-transfected cell lysates (Fig. 3C).
These results suggest that the sera from some MAR patients
contain autoantibodies against TRPM1. Due to the limited
volume of sera from the MAR patients, we could not try
immunostaining on the monkey or the mouse retina using the
serum from the patients #8 and #23.
MAR patient #8, was a 76-year-old man with a history of skin
melanoma. He had ring scotomas and abnormal ERGs indicating
that he had MAR. The other patient, MAR #23, was a 57-year-
Figure 2. Full-field ERG recordings. The rod response was recorded with a blue light at an intensity of 5.2610
23 cd-s/m
2 after 30 minutes of dark-
adaptation. The cone-rod mixed maximum response was elicited by a white flash at an intensity of 44.2 cd-s/m
2. The oscillatory potentials were
recorded with a white flash at an intensity of 44.2 cd-s/m
2 using a band-pass filter of 50–1000 Hz. The cone response and a 30 Hz flicker response
were elicited by a white stimulus of 4 cd-s/m
2 and 0.9 cd-s/m
2, respectively, on a blue background of 30 cd/m
2. Photopic long-flash ERG responses
were also elicited by long-duration flashes of 100 ms using a densely-packed array of white LEDs of 200 cd/m
2 on a white background of 30 cd/m
2.
doi:10.1371/journal.pone.0019911.g002
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abnormal color vision. He had a history of skin melanoma and
thyroid cancer. There was no other clinical information available
on these two patients because these sera were obtained from other
institutes several years before without detailed clinical information.
Discussion
PR, including MAR and CAR, presents visual disorders associated
with systemic cancer. Antibodies against retinal cells and proteins
have been detected in the sera of patients with PR suggesting an
autoimmune basis for the etiology of the PR. The autoantibodies
identified so far include rhodopsin, retinal transducin alpha and beta,
recoverin, S-arrestin, a-enolase, carbonic anhydrase II, and heat
shock protein-60 which reside abundantly in photoreceptors [1–
10,16]. MAR and CAR can cause bipolar cell dysfunction [7–12].
The results of the ERG [8,9] and immunohistochemistry [7] studies
suggested that the main target of MAR are retinal ON bipolar cells in
both the rod and cone pathways. However, autoantibodies
specificallyreactingwithabipolarcellantigenhad notbeenidentified
in the sera of patients with PR, including those with CAR and MAR.
In the current study, we identified autoantibodies against TRPM1, a
component of the ON bipolar cell transduction channel negatively
regulated by Goa in the mGluR6 signaling pathway [13–15], in the
Figure 3. Immunostaining and Western blot analysis of human TRPM1 using serum from the CAR patient. (A–C) Immunoblots of the
transfected cell lysates using an antibody against Flag tag (A), serum from CAR patient (B), and control serum (C). Arrowheads indicate the TRPM1-
3xFlag protein bands. HEK293T cells were transfected with the pCAGGS or pCAGGS-human TRPM1-3xFlag plasmid, and cells were harvested after
48 hrs. b-actin (b-act) was used for a loading control. (D–G) Confocal images of a three-year-old rhesus monkey retina immunostained with the
concentrated serum from the CAR patient (D, F) or the concentrated normal serum (E, G). Cell nuclei are visualized with DAPI. CAR patient serum
presented signals on INL cells and the inner part of the OPL (D, F). Scale bar =50 mm in (E) and 20 mm in (G).
doi:10.1371/journal.pone.0019911.g003
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exhibited a dysfunction of ON bipolar cells, and to our knowledge,
this isthe first report on an autoantibody against a bipolar cell antigen
in the serum of PR patients affecting the ON bipolar cell function.
Previously, we isolated a mouse TRPM1-L cDNA corresponding
to the human long form of TRPM1, and found that the TRPM1-L
protein is developmentally localized at the tips of the ON bipolar
dendrites co-localizing with mGluR6, but not on OFF bipolar cells
[13,14]. The TRPM1 null mutant mouse completely loses the ON
bipolar cell photoresponses to light, indicating that TRPM1 plays
a critical role in the synaptic transmission from photoreceptors to
ON-bipolar cells [13,15]. In addition, we demonstrated using a
CHO cell reconstitution system that TRPM1-L is a nonselective
cation channel which is negatively regulated by Goa downstream
of the mGluR6 signaling cascade in ON bipolar cells [13].
Recently, four groups including ours independently reported that
mutations of human TRPM1 are associated with the complete-type
of congenital stationary night blindness (cCSNB), an inherited
human retinal disease [17–20]. cCSNB is a non-progressive retinal
disease characterized by congenital night blindness with a
moderate decrease in visual acuity and myopia [21-24]. Previous
ERG studies have suggested that the defect in cCSNB patients lies
in the signal transmission from photoreceptors to ON bipolar cells
in both the rod and cone pathways [25–28]. We have identified
five different mutations in our three cCSNB patients, and have
shown that these mutations lead to either abnormal TRPM1
protein production or mislocalization of the TRPM1 protein in
bipolar cell dendrites [17]. These results suggest that TRPM1
plays a critical role in mediating the photoresponses of ON bipolar
cells in humans as well. Based on these findings, we hypothesize
that the ectopic expression of TRPM1 in tumor cells of some CAR
and MAR patients may result in aberrant production of
autoantibodies to TRPM1 through B-lymphocytic responses
[29–32]. These antibodies may react to the TRPM1 protein in
retinal ON bipolar cells resulting in dysfunction of the TRPM1
transduction cation channel downstream of the mGluR6 signaling
cascade. However, we could not confirm whether TRPM1 is
expressed in the tumor cells of the three PR patients examined in
this study [29] because tumor samples were not available.
Another question regarding the disease mechanism underlying
PR is whether the binding of TRPM1 autoantibody to bipolar cells
results in the cell death or dysfunction of bipolar cells. As far as we
examined the retinal structure of the CAR patient using a spectral
domain optical coherence tomography (SD-OCT) retinal imaging
device, the structure of the retinal bipolar cell layer appeared to be
well preserved even three months after the onset of symptoms
(Fig.1D). This suggests that the autoantibodies reacting to TRPM1
cause dysfunction of the ON bipolar transduction pathway rather
than bipolar cell death. However, further studies are needed to
clarify the exact disease mechanism.
In the sera of MAR patients, several types of autoantibodies
against retinal proteins have been reported, including the 22 kDa
neuronal antigen GNB1, rhodopsin, S-arrestin, and aldolase-A and
-C [10,16,33,34]. We initially considered that TRPM1 might be a
major MAR target antigen, because TRPM1 is exclusively
expressed in retinal ON bipolar cells. However, autoantibodies
against TRPM1 were detected in only two out of 26 MAR.
patients’ sera (7.7%, Fig. 4A, B). We tested whether the sera of one
CAR patient and 26 MAR patients recognized human mGluR6,
which is specifically expressed in ON bipolar cells, however, none
of the sera exhibited a significant band in Western blot analysis
(data not shown). Thus, antigens other than TRPM1 or mGluR6
may be involved in the pathogenesis of a large proportion of MAR.
Immunohistochemical analyses using the serum of the CAR
patient showed labeling in the inner nuclear layer and outer
plexiform layer of the adult rhesus monkey retina (Fig. 3D–G),
where the bipolar cell bodies and dendrites reside, respectively. This
immunostaining pattern is somewhat similar to our previous
immunostaining results on the mouse retina with specific antibody
against mouse TRPM1-L, which corresponds to the human TRPM1
longform[13].Otherlabelingwasalsoobservedintheamacrinecells
and ganglion cells. The reason for the immunoreactivity with these
cells is uncertain, however, it may be due to the presence of other
autoantibodies against amacrine cell and ganglion cell antigens. Lu
et al. reported the presence of various different autoantibodies in the
serum of a single PR patient [10]. If this is the case, it may explain
why our CAR patient displayed severely reduced visual sensitivities in
the visual field tests (Fig. 1A) unlike cCSNB patients with TRPM1
mutations[17].
It should be noted that we did not confirm whether there are any
antoantibodies against TRPM1 in the sera of normal subjects by
using a large number of samples. However, this possibility is thought
to be low, because Shimazaki et al. reported that the molecular
weights of the IgGs with observed anti-retinal reactivity in 92 normal
sera were smaller than 148 kDa, which is smaller than the TRPM1
molecular weight of ,200 kDa, although relatively high molecular
weight reactivity was not intensively investigated [35].
One limitation of the current study is that we could not obtain
detailed information on the two MAR patients, MAR #8a n d#23,
associated with the TRPM1 autoantibody. We confirmed that these
two patients had skin melanomas accompanying the visual
disturbances, but could not obtain a more detailed clinical history
or data on visual acuity, visual field, or ERGsbecausethesesera were
sent from different hospitals several years ago. Thus, we do not know
whether these two MAR patients really had retinal ON bipolar cell
dysfunction. Further prospective studies of the TRPM1 autoanti-
bodies in large numbers of MAR patients are needed.
Figure 4. Western blot analysis of human TRPM1 using sera
from the MAR patients. (A, B) Immunoblots of the transfected cell
lysates using sera from MAR patient #8 (A) and MAR patient #23 (B).
HEK293T cells were transfected with pCAGGS or pCAGGS-human
TRPM1-3xFlag plasmid, and cells were harvested after 48 hrs. Arrow-
heads indicate the TRPM1-3xFlag protein bands. b-actin (b-act) was
used for a loading control.
doi:10.1371/journal.pone.0019911.g004
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PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e19911In conclusion, our study suggests that TRPM1 may be one of
the causative antigens responsible for PR associated with ON
bipolar cell dysfunction.
Note added in proof
During the course of revision process of this manuscript,
Dhingra et al. (J. Neurosci. 31, 3962–3967, 2011) independently
reported the presence of autoantibodies against TRPM1 in two
MAR patients. Our study reports on autoantibodies against
TRPM1 in CAR serum in addition to MAR sera.
Materials and Methods
Subjects
The Nagoya University Hospital Ethics Review Board ap-
proved this study (approval ID 1131). Of the PR patients that were
examined in the Nagoya University Hospital, one PR patient with
lung cancer and ON bipolar cell dysfunction was studied in detail.
The examinations included routine ophthalmological and electro-
physiological tests. In addition, immunohistochemical and West-
ern blot analyses were performed using the serum of this patient.
The procedures used conformed to the tenets of the Declaration of
Helsinki of the World Medical Association. A written informed
consent was obtained from the patient after he was provided with
sufficient information on the procedures to be used.
We also obtained sera of 26 patients with MAR from two
hospitals in Japan (Chiba University Hospital and Iwate Medical
University Hospital) and Ocular Immunology Laboratory in the
USA (Casey Eye Institute) for Western blot analysis.
Ophthalmologic examinations
The ophthalmologic examination included best-corrected visual
acuity, biomicroscopy, ophthalmoscopy, fundus photography, fluo-
rescein angiography, static perimetry, and spectral-domain optical
coherence tomography (SD-OCT). Static visual fields were obtained
with the Humphrey 30-2 program (Carl Zeiss, Dublin, USA),and the
resultsareshowningrayscale.SD-OCTwasperformedwitha9-mm
horizontal scan through the midline with 50 averages (Spectralis
HRA+OCT; Heidelberg Engineering, Vista, CA).
Electroretinograms (ERG)
Full-field ERGs were elicited with a Ganzfeld dome and
recorded with a Burian-Allen bipolar contact lens electrode. The
ground electrode was attached to the ipsilateral ear.
After 30 minutes of dark-adaptation, a rod response was elicited
with a blue light at an intensity of 5.2610
23 cd-s/m
2. A cone-rod
mixed maximum response was elicited by a white flash at an
intensity of 44.2 cd-s/m
2. A cone response and a 30 Hz flicker
response were elicited by a white stimulus of 4 cd-s/m
2 and
0.9 cd-s/m
2, respectively, on a blue background of 30 cd/m
2.
Full-field cone ERGs were also elicited by long-duration flashes of
100 ms using a densely packed array of white LEDs. The array
was positioned at the top of the Ganzfeld dome and covered by a
diffuser. The stimulus intensity and background illumination
measured in the dome was 200 cd/m
2 and 30 cd/m
2, respectively.
Responses were amplified by 10K and the band pass was set to 0.3
to 1000 Hz. The data were digitized at 4.3 kHz, and 5 to 20
responses were averaged (Neuropack, Nihonkohden, Tokyo,
Japan).
Immunohistochemistry
For immunohistochemistry, patient and normal sera (300 ml)
were purified using the Melon Gel IgG purification kit according
to the manufacturer’s protocol (Pierce Biotechnology, Rockford,
IL) to remove IgM, and purified sera were concentrated by
Amicon Ultra 100 (Millipore, MA). The rhesus monkey eye cup
was fixed with 4% paraformaldehyde in PBS for 30 min at 4uC.
The samples were cryoprotected with 30% sucrose in PBS and
embedded in OCT compound (Sakura Finetechnical, Tokyo,
Japan). These tissues were sliced with a Microm HM 560 cryostat
microtome (Microm Laborgera ¨te GmbH, Walldorf, Germany)
into 14 mm. Sections were washed twice in PBS for 5 min,
permeabilized with 0.1% Triton-X100/PBS, then washed with
PBS 3 times for 5 min, and incubated with PBS containing 4%
donkey serum for 1 hr to block samples. For the immunoreaction,
the samples were incubated with a purified normal or CAR serum
(1:300) diluted in blocking buffer at 4uC overnight. After PBS-
washing, these samples were incubated with a DyLight-488
conjugated donkey anti-human IgG (H+L) (1:400) as a secondary
antibody (Jackson Immunoresearch Laboratories) at room tem-
perature for 1 hr and washed with PBS.
Transfection and Western blot analyses
HEK293T cells were cultured in D-MEM containing 10% fetal
bovine serum (FBS; Nissui, Tokyo, Japan). These cells were grown
under 5% carbon dioxide at 37uC. The calcium phosphate
method was used to transfect the cells. Transfected cells were
incubated at 37uC for 48 hrs, and then harvested for further
analysis. The proteins extracted from the cells were separated by
SDS–PAGE on a 7.5% precast gel (ATTO, Tokyo, Japan), and
then transferred to a polyvinylidene difluoride membrane using
the Invitrogen iBlot system (Invitrogen, Carlsbad, CA, USA). The
membrane was incubated with primary antibodies, mouse anti-
Flag (1:1,000; Sigma, St Louis, MO), sera from patients (1:100),
normal human serum (1:100), or mouse anti-b-actin (1:5,000;
Sigma). The membrane was then incubated with a horseradish
peroxidase-conjugated goat anti-mouse IgG (1:10,000; Zymed
Laboratories, San Francisco, CA) or donkey anti-human IgG
(1:10,000; Jackson Immuno Research Laboratories, West Grove,
PA) as secondary antibodies. The bands were developed using
Chemi-Lumi One L (Nacalai Tesque, Kyoto, Japan).
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